

# Use of aspirin for the prevention of preeclampsia in twin pregnancies

|  |   |   |
|--|---|---|
| <b>Submission date</b><br>05/08/2022   | <b>Recruitment status</b><br>Recruiting               | <input checked="" type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol                       |
| <b>Registration date</b><br>22/08/2022 | <b>Overall study status</b><br>Ongoing                | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                                  |
| <b>Last Edited</b><br>04/12/2025       | <b>Condition category</b><br>Pregnancy and Childbirth | <input type="checkbox"/> Individual participant data<br><input checked="" type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

Preeclampsia (PE) is a medical condition that can happen during pregnancy after 20 weeks and it is characterised by high blood pressure and the presence of protein in the urine or in its absence the finding of maternal organ dysfunction. PE is one of the leading causes of maternal and perinatal death and disabilities. There is extensive evidence that in singleton high-risk pregnancies for PE, the use of aspirin (150 mg/day from 12 until 36 weeks of gestation) reduces the chances of developing PE before 32 weeks by 89% and PE before 37 weeks by 62%. The rate of PE in twin pregnancies is about 9%, which is 3–times higher than in singleton pregnancies. Few studies investigated the use of aspirin in reducing the risk of PE in twin pregnancies, but the results are inconsistent with the findings in singleton pregnancies. Therefore, the aim of this study is to determine whether taking low-dose aspirin can reduce the risk of PE in twin pregnancies.

### Who can participate?

Anyone pregnant with twins, aged over 18 years old and had a first-trimester scan between 11+2 - 13+6 weeks of pregnancy

### What does the study involve?

Participants will be randomised and will take 2 tablets per day, either Aspirin or placebo, from 14+3 weeks until 36 weeks of pregnancy or delivery. There will be 3 telephone calls and 4 follow-up visits that will happen at the same time as the regular scan appointments.

### What are the possible benefits and risks of participating?

The possible benefits of participating include a reduction in the chances of developing preeclampsia, which can have a positive impact on the health of both the mothers and their children. The possible risks include potential pain from the blood collection at 3 of the clinical visits (optional). From taking the tablets, there are additional risks of developing: allergic reactions, stomach ache, nausea and gastric bleeding, and increased vaginal bleeding before and after delivery. Based on currently available evidence, no major risks are anticipated.

### Where is the study run from?

Fetal Medicine Foundation (UK)

When is the study starting and how long is it expected to run for?  
August 2019 to October 2028

Who is funding the study?  
Fetal Medicine Foundation (UK)

Who is the main contact?  
Prof. Kypros Nicolaides  
kypros@fetalmedicine.com

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Kypros Nicolaides

**Contact details**  
Harris Birthright Research Centre for Fetal Medicine  
King's College Hospital  
London  
United Kingdom  
SE5 8BB  
+44 (0)20 3299 8256  
kypros@fetalmedicine.com

**Type(s)**  
Scientific

**Contact name**  
Dr Catalina De Paco

**Contact details**  
Fetal Medicine Unit  
Hospital Universitario Virgen de la Arrixaca  
Ctra. Madrid-Cartagena  
Murcia  
Spain  
30120  
+34 (0)676 67 26 17  
catalina.de1@um.es

**Type(s)**  
Scientific

**Contact name**  
Dr Argyro Syngelaki

**Contact details**

Harris Birthright Research Centre for Fetal Medicine  
King's College Hospital  
London  
United Kingdom  
SE5 8BB  
+44 (0)20 3299 7164  
argyro.syngelaki@nhs.net

**Type(s)**

Scientific

**Contact name**

Ms Angel Leung

**Contact details**

Fetal Medicine Research Institute  
16-20 Windsor Walk  
London  
United Kingdom  
SE5 8BB  
+44 (0)7857306268  
angel.leung2@nhs.net

## Additional identifiers

**Clinical Trials Information System (CTIS)**

2019-003341-15

**Integrated Research Application System (IRAS)**

269958

**Central Portfolio Management System (CPMS)**

50869

**Integrated Research Application System (IRAS)**

269958

## Study information

**Scientific Title**

Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial (ASPRE-T)

**Acronym**

ASPRE-T

**Study objectives**

To evaluate the effectiveness of low-dose aspirin in reducing the risk of preterm preeclampsia in twin pregnancy, the study will compare the results of the interventional group with the results of the placebo group

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 12/04/2022, London - Surrey Borders Research Ethics Committee (The Old Chapel, Royal Standard Place, HRA, Nottingham, NG1 6FS, UK; +44 (0)20 7104 8057; surreyboundaries.rec@hra.nhs.uk), ref: 21/LO/0757

**Study design**

Randomized case-controlled study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Preterm preeclampsia in twin pregnancy

**Interventions**

Women will be recruited from their routine first-trimester scan where the eligibility criteria will be assessed. Women who accept to take part in the trial and sign the consent form will agree to have some of their blood stored for future analysis. They routinely will have bloods taken for screening of trisomies and at the same time will be consented for bloods for the research study. Routinely in the units involved, they will also have basic clinical investigations of blood pressure, height, weight and a medical history taken. Upon participation, they will then be randomised to placebo or aspirin and asked to take this until 36 weeks of gestation.

From this point on, women will continue on their normal follow-up pathway for twin pregnancies. Those with monochorionic pregnancies will actually be seen more often for clinical needs, but in terms of research follow-up, in addition to their routine scans, and clinical investigations at the 20-, 28-, 31- and 35-week time points, we will determine compliance of medication by counting their remaining tablets and assessing their diary cards for adverse events. The only additional blood sampling we will be asking for will be at the 20- and 32-week visits.

They will receive telephone interviews at 15 and 24 weeks of gestation, followed by a call 4 weeks after the last dose of the investigational medicinal product (IMP). The purpose of these will be reminders to take the medication, but more importantly to assess for adverse events.

**Intervention Type**

Other

**Primary outcome(s)**

Incidence of preeclampsia (PE) requiring delivery before 37 weeks gestation in twin pregnancies, measured by examination of hospital records and patient interviews. PE will be defined by the American College of Obstetricians and Gynecologists (ACOG 2013).

**Key secondary outcome(s)**

All measured by examination of hospital records and patient interviews

1. Incidence of PE requiring delivery before 32 weeks, 34 weeks, 37 weeks and at any gestation,  
2. For all features of severe PE the timepoint is from diagnosis of PE until maternal discharge from hospital- Features of severe PE include:

2.1. Stroke

2.2. Eclampsia

2.3. Systolic blood pressure >160 mmHg on at least one occasion

2.4. Systolic blood pressure >160 mmHg on at least one occasion

2.5. Respiratory failure

2.6. Myocardial ischemia or infarction

2.7. Pulmonary edema

2.8. Hepatic dysfunction

2.9. Hepatic hematoma or rupture

2.10. Platelet count <100 x 10<sup>9</sup>/litre

2.11. Abnormal liver function enzymes (ALT or AST >67 iu/litre),

2.12. Acute kidney injury

2.13. Creatinine >150 µmol/L

2.14. Cortical blindness

2.15. Retinal detachment

2.16. Transfusion of any blood products,

2.17. HELLP syndrome,

2.18. Placental abruption

2.19. Postpartum hemorrhage

2.20. Intensive therapy or high-dependency unit admission;

2.21. Confirmed sepsis

2.22. Total number of nights in hospital

3. Gestational hypertension (GH) requiring delivery before 37 weeks' gestation defined by ACOG 2013

4. Birth before 32, 34 and 37 weeks, either:

4.1. Spontaneous

4.2. Iatrogenic for PE, GH or Fetal Growth Restriction (FGR)

4.3. Iatrogenic for other reasons

5. Death of one twin and/or both twins at timepoint before discharge from hospital

5.1. Miscarriage of the whole pregnancy or death of one twin before 24 weeks' gestation

5.2. Stillbirth or neonatal death of one or both twins at 32 weeks, 34 weeks, 37 weeks and at any gestation

6. Birthweight <3rd, <5th and <10th percentile for gestational age measured by Fetal Medicine Foundation birthweight chart (Nicolaidis et al., 2018)

7. Placental abruption timepoint at 32 weeks, 34 weeks, 37 weeks and at any gestation

8. Postpartum hemorrhage timepoint first 24 hours after delivery

9. Neonatal morbidity including any of the following measured by examination of hospital records and patients' interviews, timepoint until discharge from hospital after birth:

9.1. Intraventricular hemorrhage (IVH) grade II or above

9.2. Neonatal sepsis

9.3. Encephalopathy

9.4. Neonatal seizures

9.5. Anaemia

9.6. Respiratory distress syndrome

9.7. Necrotizing enterocolitis

9.8. Composite of any of the above

10. Neonatal therapy including any of the following measured by examination of hospital records and patients' interviews, timepoint until discharge from hospital after birth:

- 10.1. Neonatal intensive care unit admission
- 10.2. Ventilation
- 10.3. Composite of any of the above
- 10.4. Length of stay in neonatal intensive care unit

**Completion date**

31/10/2028

## Eligibility

**Key inclusion criteria**

- 1. Aged 18 years old and over
- 2. DCDA or MCDA twin pregnancies
- 3. Both live fetuses at 11+2-13+6 weeks of gestation
- 4. Informed and written consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

55 years

**Sex**

Female

**Total final enrolment**

0

**Key exclusion criteria**

- 1. Monoamniotic twins
- 2. Triplet pregnancies that had undergone embryo reduction to twins or with one vanishing twin
- 3. Pregnancies complicated by a major fetal abnormality or nuchal translucency thickness > 3.5 mm identified at the 11+2-13+6 weeks scan
- 4. MCDA twin pregnancies in which there are early signs of TTTS or sFGR defined by a 20% discordance in CRL at the 11+2-13+6 weeks' scan
- 5. Those who lack capacity and who are unable to provide informed consent to take part
- 6. Women taking low-dose aspirin regularly (administration must have ceased > 7 days prior to randomization)
- 7. Participation in another drug trial within the previous 7 days
- 8. Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia or concurrent anticoagulant therapy

9. Active or history of recurrent peptic ulceration and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages
10. Patients who are suffering from known gout, severe hepatic impairment or severe renal impairment
11. Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria) or to any excipients (see section 6.1 of the SmPC for details)
12. Patients on long-term non-steroidal anti-inflammatory medication
13. Not fluent in local language and absence of an interpreter
14. Any other reason the clinical investigators think will prevent the potential participant from complying with the trial protocol

**Date of first enrolment**

30/08/2022

**Date of final enrolment**

30/09/2028

## **Locations**

**Countries of recruitment**

United Kingdom

England

Austria

Belgium

Bulgaria

Denmark

Germany

Greece

Hungary

Ireland

Israel

Italy

Poland

Portugal

Spain

**Study participating centre**  
**North Middlesex University Hospital Trust**  
North Middlesex Hospital  
Sterling Way  
London  
England  
N18 1QX

**Study participating centre**  
**Southend University Hospital**  
Prittlewell Chase  
Westcliff-On-Sea  
Essex  
England  
SS0 0RY

**Study participating centre**  
**King's College Hospital Nhs Foundation Trust**  
Denmark Hill  
London  
England  
SE5 9RS

**Study participating centre**  
**Medway Maritime Hospital**  
Windmill Road  
Gillingham  
England  
ME7 5NY

**Study participating centre**  
**Homerton University Hospital**  
Homerton Row  
London  
England  
E9 6SR

**Study participating centre**



**St Thomas Hospital**  
Westminster Bridge Road  
London  
England  
SE1 7EH

**Study participating centre**  
**University Hospital Lewisham**  
Lewisham High Street  
London  
England  
SE13 6LH

**Study participating centre**  
**Birmingham Heartlands Hospital**  
Bordesley Green East  
Bordesley Green  
Birmingham  
England  
B9 5SS

**Study participating centre**  
**Queen Elizabeth Hospital**  
Lewisham and Greenwich NHS Trust  
Stadium Rd  
London  
England  
SE18 4QH

**Study participating centre**  
**Queens Hospital**  
Barking Havering and Redbridge University Hospital Trust  
Rom Valley Way  
Romford  
England  
RM7 0AG

## **Sponsor information**

**Organisation**

Fundación para la Formación e Investigación Sanitarias de la Región de Murcia

ROR

<https://ror.org/05m5has32>

## Funder(s)

### Funder type

Charity

### Funder Name

Fetal Medicine Foundation; Grant Codes: N/K

### Alternative Name(s)

FMF

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Trusts, charities, foundations (both public and private)

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### Study outputs

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">HRA research summary</a>          |                               |              | 28/06/2023 | No             | No              |
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |
| <a href="#">Study website</a>                 | Study website                 | 11/11/2025   | 11/11/2025 | No             | Yes             |